Log in to search using one of your social media accounts:

 

Drug Safety update: Oral tacrolimus products: reminder to prescribe and dispense by brand name only
The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a drug safety update for oral tacrolimus products. Inadvertent switching between tacrolimus products has been associated with (Source: Royal Pharmaceutical Society News)
Source: Royal Pharmaceutical Society News - November 24, 2017 Category: Drugs & Pharmacology Source Type: news

Astagraf XL (Tacrolimus Extended-release Capsules) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - December 8, 2016 Category: Drugs & Pharmacology Source Type: news

Protopic (Tacrolimus) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - December 8, 2016 Category: Drugs & Pharmacology Source Type: news

tacrolimus (Prograf, Astagraf XL, Envarsus XR)
Title: tacrolimus (Prograf, Astagraf XL, Envarsus XR)Category: MedicationsCreated: 12/6/1998 12:00:00 AMLast Editorial Review: 9/29/2016 12:00:00 AM (Source: MedicineNet Digestion General)
Source: MedicineNet Digestion General - September 29, 2016 Category: Nutrition Source Type: news

Prograf (Tacrolimus) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - September 26, 2016 Category: Drugs & Pharmacology Source Type: news

Envarsus XR (Tacrolimus Extended-release Tablets) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - July 6, 2016 Category: Drugs & Pharmacology Source Type: news

Immunosuppressive medication effectively treats ocular graft-versus-host-disease
A complication associated with bone marrow transplantation, graft-versus-host-disease, occurs when a transplanted immune system attacks certain parts of a host's body, and may cause severe dry eye and damage to the cornea. A clinical trial showed that topical doses of ultra low-dose tacrolimus, an immunosuppressive medication, is equally effective and showed fewer hypertensive side effects in treating ocular symptoms associated with graft-versus-host-disease than methylprednisolone, a steroid medication. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - April 13, 2016 Category: Science Source Type: news

Immunosuppressive medication effectively treats ocular graft-versus-host-disease
(Massachusetts Eye and Ear Infirmary) A complication associated with bone marrow transplantation, graft-versus-host-disease, occurs when a transplanted immune system attacks certain parts of a host's body, and may cause severe dry eye and damage to the cornea. A clinical trial at Massachusetts Eye and Ear showed that topical doses of ultra low-dose tacrolimus, an immunosuppressive medication, is equally effective and showed fewer hypertensive side effects in treating ocular symptoms associated with graft-versus-host-disease than methylprednisolone, a steroid medication. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 13, 2016 Category: Global & Universal Source Type: news

UCLA study yields the key to effective personalized medicine
This study demonstrated the ability to use a patient’s phenotype to personalize their treatment in an actionable manner without the need for genome profiling,” said Ho, a corresponding author of the study. “We also have shown that PPM can be extended to optimize combination therapy for a wide spectrum of diseases.” Showing that every patient’s response to medical treatment — for diseases ranging from cancer to infectious diseases, or following an organ transplant — produces a parabola-shaped graph is a landmark advance, Ho said. Among other things, the appr...
Source: UCLA Newsroom: Health Sciences - April 6, 2016 Category: Universities & Medical Training Source Type: news

Feature Review: Topical treatments for psoriasis of the scalp
 Topical treatments for psoriasis of the scalpWhat are the most effective and safest treatments?                                                                                         ...
Source: Cochrane News and Events - March 4, 2016 Category: Information Technology Authors: mumoquit at cochrane.org Source Type: news

VIDEO: What’s new on atopic dermatitis drugs and cancer concerns?
WAIKOLOA, HAWAII – Topical calcineurin inhibitors’ boxed warnings give many patients and physicians pause over cancer concerns – but a new database analysis may put some minds at ease about the drugs’ use for atopic dermatitis. “Pimecrolimus and tacrolimus are given topically, not internally –... (Source: Skin and Allergy News)
Source: Skin and Allergy News - February 17, 2016 Category: Dermatology Source Type: news

Common cause for complications after kidney transplantation identified
(University of Basel) The BK polyomavirus often causes complications after kidney transplantation. The research group of Professor Hans H. Hirsch from the Department of Biomedicine at the University of Basel has now been able to show, that the immunosuppressive drug Tacrolimus directly activates the replication of the virus and could thus be responsible for these complications. The American Journal of Transplantation has published the study. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - November 23, 2015 Category: Infectious Diseases Source Type: news

LEO Pharma to Acquire Global Dermatology Portfolio from Astellas
BALLERUP, Denmark, November 11, 2015 -- (Healthcare Sales & Marketing Network) -- LEO Pharma A/S, a global healthcare company dedicated to helping people achieve healthy skin, and Japanese pharmaceutical company Astellas Pharma Inc. today announced that t... Biopharmaceuticals, Dermatology, AcquisitionsLEO Pharma, Astellas Pharma, Protopic (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 11, 2015 Category: Pharmaceuticals Source Type: news

Scientists identify potential birth control 'pill' for men
Two drugs that help suppress the immune system in organ transplant patients may have a future as the long-sought birth control "pill" for men, new research suggests. The drugs – cyclosporine A (also known as CsA) and FK506 (also known as tacrolimus) – are given to transplant recipients to reduce... (Source: Los Angeles Times - Science)
Source: Los Angeles Times - Science - October 1, 2015 Category: Science Authors: Karen Kaplan Source Type: news

Envarsus XR (Tacrolimus Extended-release Tablets) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - August 3, 2015 Category: Drugs & Pharmacology Source Type: news

Tacrolimus Comes Out Tops for Lupus Nephritis (CME/CE)
(MedPage Today) -- Meta-analysis compares the available immunosuppressants. (Source: MedPage Today Rheumatology)
Source: MedPage Today Rheumatology - July 25, 2015 Category: Rheumatology Source Type: news

Veloxis's Envarsus XR gets FDA approval to treat kidney transplant patients
Denmark-based Veloxis Pharmaceuticals has received approval from the US Food and Drug Administration (FDA) for its Envarsus XR (tacrolimus extended-release tablets) to treat kidney transplant patients. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - July 12, 2015 Category: Pharmaceuticals Source Type: news

Tacrolimus Market (Immunosuppressive Drug) 2020 Forecasts with 6...
2015 Market Research Report on Global Tacrolimus Industry is the new addition to pharmaceuticals market intelligence collection of DeepResearchReports.com and its industry research library focusing on...(PRWeb July 09, 2015)Read the full story at http://www.prweb.com/releases/global-tacrolimus-market/2020-forecast-analysis/prweb12836245.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - July 12, 2015 Category: Pharmaceuticals Source Type: news

Tacrolimus Won't Derail Pneumococcus Vaccine (CME/CE)
(MedPage Today) -- But there's diminished response in RA patients on it with methotrexate. (Source: MedPage Today Geriatrics)
Source: MedPage Today Geriatrics - June 14, 2015 Category: Geriatrics Source Type: news

The Emerging Role of Tacrolimus in Myasthenia GravisThe Emerging Role of Tacrolimus in Myasthenia Gravis
Is the immunosuppressive drug tacrolimus beneficial in reducing symptoms of myasthenia gravis? This review summarizes the latest evidence. Therapeutic Advances in Neurological Disorders (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 26, 2015 Category: Consumer Health News Tags: Neurology & Neurosurgery Journal Article Source Type: news

Generic transplant drugs as good as brand name, experts say
Scientists have found that generic formulations of tacrolimus, a drug used post-transplant to lower the risk of organ rejection, are just as good as the name-brand version. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - May 3, 2015 Category: Science Source Type: news

Study: Generic transplant drugs as good as brand name
(University of Cincinnati Academic Health Center) A University of Cincinnati-led research team has found that generic formulations of tacrolimus, a drug used post-transplant to lower the risk of organ rejection, are just as good as the name-brand version. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 3, 2015 Category: Global & Universal Source Type: news

Selten Pharma, Inc. Receives Orphan Drug Designation From U.S. FDA for the Treatment of Pulmonary Arterial Hypertension
SARATOGA, Calif., March 18, 2015 -- (Healthcare Sales & Marketing Network) -- Selten Pharma, Inc., a privatively held biopharmaceutical company focused on the development and commercialization of therapies for the treatment of rare diseases, announced tod... Biopharmaceuticals, FDASelten Pharma, tacrolimus, pulmonary arterial hypertension (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 18, 2015 Category: Pharmaceuticals Source Type: news

tacrolimus, Prograf, Astagraf XL, Hectoria
Title: tacrolimus, Prograf, Astagraf XL, HectoriaCategory: MedicationsCreated: 12/6/1998 12:00:00 AMLast Editorial Review: 2/17/2015 12:00:00 AM (Source: MedicineNet Crohn's Disease General)
Source: MedicineNet Crohn's Disease General - February 17, 2015 Category: Gastroenterology Source Type: news

Tacrolimus Similar to MMF as Induction for Lupus NephritisTacrolimus Similar to MMF as Induction for Lupus Nephritis
In combination with steroids, tacrolimus (TAC) seems to have similar efficacy and safety as mycophenolate mofetil (MMF) as induction therapy for lupus nephritis, researchers reported December 30 in Annals of the Rheumatic Diseases Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 10, 2015 Category: Consumer Health News Tags: Rheumatology News Source Type: news

Tacrolimus for Induction in Lupus Nephritis? (CME/CE)
(MedPage Today) -- Patients did just as well with tacrolimus as with mycophenolate mofetil. (Source: MedPage Today Rheumatology)
Source: MedPage Today Rheumatology - January 8, 2015 Category: Rheumatology Source Type: news

Prograf Aids in Myopathy-Related Lung Disease
(MedPage Today) -- Study "provides some reassurance" on use of tacrolimus. (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - December 30, 2014 Category: Primary Care Source Type: news

Maintenance tacrolimus for eczema boosts quality of life
AMSTERDAM – Twice-weekly proactive maintenance therapy with 0.1% tacrolimus ointment in adults with moderate to severe atopic dermatitis resulted in dramatic improvement in self-reported quality of life in a 12-month observational study. This prospective study was designed to assess patients’ own...googletag.display('div-gpt-ad-cta'); (Source: Skin and Allergy News)
Source: Skin and Allergy News - December 15, 2014 Category: Dermatology Tags: FPN News FPN Dermatology IMN News IMN Dermatology SAN Clinical News SAN News SAN Atopic Dermatitis European Academy of Dermatology and Venereology Source Type: news

Lupus Nephritis: Multidrug Induction Ups Complete Responses Lupus Nephritis: Multidrug Induction Ups Complete Responses
A combination of tacrolimus, mycophenolate mofetil, and steroid resulted in higher remission rates than cyclophosphamide plus steroid. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 15, 2014 Category: Consumer Health News Tags: Nephrology News Source Type: news

Strides Arcolab gets USFDA approval for Tacrolimus capsules
The product will be manufactured at the company's oral dosage facility at Bangalore and marketed directly by Strides in the US market. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - July 23, 2014 Category: Pharmaceuticals Source Type: news

Topical Tacrolimus 0.03% in Vernal KeratoconjunctivitisTopical Tacrolimus 0.03% in Vernal Keratoconjunctivitis
This study compares the efficacy of this agent when used alone or combined with olopatadine. Eye & Contact Lens (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 20, 2014 Category: Consumer Health News Tags: Ophthalmology Journal Article Source Type: news

Veloxis Announces Scientific Publication of Phase II Study Demonstrating Conversion from Twice-Daily Tacrolimus to Once-Daily Envarsus® in Liver Transplant Patients
(Source: Medical News (via PRIMEZONE))
Source: Medical News (via PRIMEZONE) - April 28, 2014 Category: Pharmaceuticals Source Type: news

Tacrolimus Eye Drops for Refractory Allergic Ocular DiseasesTacrolimus Eye Drops for Refractory Allergic Ocular Diseases
Use of tacrolimus 0.1% eye drops is associated with significant improvement of refractory allergic conjunctivitis with proliferative lesions and/or corneal involvement, according to an observational study from Japan. Reuters Health Information (Source: Medscape Ophthalmology Headlines)
Source: Medscape Ophthalmology Headlines - April 22, 2014 Category: Opthalmology Tags: Ophthalmology News Source Type: news

FDA awards $2.25M grant to study immunosuppresive drug in high-risk patients
(University of Cincinnati Academic Health Center) University of Cincinnati Research Professor Rita Alloway, PharmD, has been awarded a $2.25 million grant from the U.S. Food and Drug Administration to study the safety and efficacy of the generic immunosuppressive drug tacrolimus in transplant patients. As a "cornerstone drug" in post-transplant immunosuppression, tacrolimus is used to lower the risk of organ rejection -- these studies are aimed to address public concerns regarding the use of new generic formulations in high-risk transplant recipients. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 7, 2013 Category: Global & Universal Source Type: news

Prophylaxis of fungal infections in liver transplant patients
New data presented at the 16th Congress of the European Society for Organ Transplantation (ESOT) demonstrate that in liver transplant patients, initiating ADVAGRAF™ prolonged-release capsules (tacrolimus) therapy immediately post transplant, at a dose 25% lower than the upper recommended limit,(8) in combination with basiliximab, results in significantly better renal function and a lower incidence of acute organ rejection when compared with standard dose ADVAGRAF therapy.(9) Furthermore, delaying the introduction of ADVAGRAF post transplant gives no additional advantage in terms of renal function.(9) (Source: Pharmacy Europe)
Source: Pharmacy Europe - September 12, 2013 Category: Drugs & Pharmacology Authors: ebercott Tags: *** Editor's Pick Transplantation Latest News Source Type: news

Tacrolimus Dose in Pediatric Liver TransplantationTacrolimus Dose in Pediatric Liver Transplantation
Tacrolimus has become the mainstay of immunosuppressive treatment in pediatric liver transplantation. How does the CYP3A5 genotype effect tacrolimus dose requirements? Pharmacogenomics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 8, 2013 Category: Consumer Health News Tags: Transplantation Journal Article Source Type: news

Astagraf XL (Tacrolimus Extended-release Capsules) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - August 2, 2013 Category: Drugs & Pharmacology Source Type: news

Long-Release Tacrolimus Wins FDA Nod
(MedPage Today) -- An extended-release formulation of tacrolimus (Astagraf XL) for preventing kidney transplant rejection has been approved by the FDA, its manufacturer said. (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - July 22, 2013 Category: Primary Care Source Type: news

Roche launches new tests for monitoring transplant patients on immunosuppressive therapy
Roche today announced the global launch (except US) of two new highly sensitive therapeutic drug monitoring tests for the immunosuppressant medicines tacrolimus and cyclosporine. The new Elecsys Tacrolimus and Cyclosporine tests provide healthcare professionals with more accurate and reliable results. They are made for use on Roche’s cobas modular analysers, thus also supporting enhanced workflow and efficiency in medical laboratories. (Source: Roche Investor Update)
Source: Roche Investor Update - July 19, 2013 Category: Pharmaceuticals Source Type: news

Roche launches new tests for monitoring transplant patients on immunosuppressive therapy
Roche today announced the global launch (except US) of two new highly sensitive therapeutic drug monitoring tests for the immunosuppressant medicines tacrolimus and cyclosporine. The new Elecsys Tacrolimus and Cyclosporine tests provide healthcare professionals with more accurate and reliable results. They are made for use on Roche’s cobas modular analysers, thus also supporting enhanced workflow and efficiency in medical laboratories. (Source: Roche Media News)
Source: Roche Media News - July 19, 2013 Category: Pharmaceuticals Source Type: news

New Automated Immunosuppressive Drug Assays Improve Therapeutic Drug Monitoring for Transplant Patients
For the first time, certain immunosuppressive drug (ISD) assays can now be performed automatically on cobas® modular platforms, allowing laboratories to consolidate testing for a wide range of transplant testing/monitoring assays onto a single platform. The new Roche automated assays for tacrolimus and cyclosporine will enhance therapeutic drug monitoring (TDM) of transplant recipients by providing the consistency and accuracy of an automated assay, while enhancing workflows, auditing and reporting capabilities in the laboratory. (Source: Pharmaceutical Online News)
Source: Pharmaceutical Online News - July 2, 2013 Category: Pharmaceuticals Source Type: news

Infant Breast Milk Exposure to Tacrolimus Negligible Infant Breast Milk Exposure to Tacrolimus Negligible
A new study has found that infant exposure to tacrolimus during breast-feeding is minimal and blood levels of the drug are comparable to those found in bottle-fed infants. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 30, 2013 Category: Consumer Health News Tags: Pediatrics News Source Type: news

Tacrolimus breast milk transfer concerns allayed
Breastfeeding mothers taking tacrolimus do not pass the immunosuppressant on to their babies when breastfeeding, study results show. (Source: MedWire News - Ob/Gyn)
Source: MedWire News - Ob/Gyn - January 30, 2013 Category: OBGYN Source Type: news

Tacrolimus breast milk transfer concerns allayed
Breastfeeding mothers taking tacrolimus do not pass the immunosuppressant on to their babies when breastfeeding, study results show. (Source: MedWire News - Pediatrics)
Source: MedWire News - Pediatrics - January 29, 2013 Category: Pediatrics Source Type: news

Mothers Taking Immunosuppressant Drug Ok To Breast Feed
Women taking the immunosuppressant tacrolimus can rest assured that breast feeding will not elevate their babies' exposure to the drug, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society of Nephrology (CJASN). The findings are good news for young women who have received an organ transplant in the past or who are taking the drug for other reasons... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - January 28, 2013 Category: Consumer Health News Tags: Women's Health / Gynecology Source Type: news

Breastfeeding OK for mothers taking immunosuppressant drug, study suggests
Women taking the immunosuppressant tacrolimus can rest assured that breast feeding will not elevate their babies' exposure to the drug, according to a new study. The findings are good news for young women who have received an organ transplant in the past or who are taking the drug for other reasons. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - January 24, 2013 Category: Science Source Type: news

UPDATE: After liver transplant for HCV, better antiviral results with cyclosporine
NEW YORK (Reuters Health) - In patients transplanted for hepatitis C cirrhosis, the virus inevitably recurs. Now a new meta-analysis suggests that cyclosporine-based immunosuppression may be associated with a better response to antiviral therapy after transplant than tacrolimus-based protocols. (Source: Modern Medicine)
Source: Modern Medicine - January 2, 2013 Category: Journals (General) Source Type: news

After liver transplant for HCV, better antiviral results with cyclosporine
NEW YORK (Reuters Health) - In patients transplanted for hepatitis C cirrhosis, the virus inevitably recurs. Now a new meta-analysis suggests that cyclosporine-based immunosuppression may be associated with a better response to antiviral therapy after transplant than tacrolimus-based protocols. (Source: Modern Medicine)
Source: Modern Medicine - January 2, 2013 Category: Journals (General) Source Type: news